We have previously found that CaSR activation with a calcimimetic worsened clinical symptoms in a mouse model of colitis (Elajnaf et al., 2019), and upregulated various inflammatory pathways in CaSR-transfected human colorectal cancer cells (Iamartino et al., 2020). This evidence concerns the gene CASR and colitis.